Structural characterization and antimycobacterial evaluation of a benzimidazole analogue of the antituberculosis clinical drug candidate TBA-7371.

The crystal structure and in vitro antimycobacterial properties of N-(2-fluoroethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-1H-benzo[d]imidazole-4-carboxamide (C17H₁₈FN₅O₂, 1), a previously reported benzimidazoleanalogue of the 1,4-azaindole-based antituberculosis drug candidate TBA-7371, are reported. The structure determination was achieved using Hirshfeld atomrefinement. Compound 1 crystallizes in the triclinic system (space group P1)with two molecules in the asymmetric unit (Z0 = 2). The two crystallographicallydistinct molecules exhibit a similar conformation with the amide groups in a Zconformation, forming an intramolecular N_amide--H· · ·N_{benzimidazole} hydrogenbond. The most significant supramolecular feature in the solid-state is arelatively short C_{benzimidazole}--H· · ·N_pyrimidine hydrogen bond. Antimycobacterialtesting confirmed in vitro activity against Mycobacterium smegmatis, but nogrowth inhibtion of Mycobacterium abscessus was found. [ABSTRACT FROM AUTHOR]